Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046252007> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2046252007 endingPage "105" @default.
- W2046252007 startingPage "100" @default.
- W2046252007 abstract "Purpose. The purpose of this study was to assess the impact of the selective serotonin-reuptake inhibitor (SSRI) sertraline (SRT) on the severity and frequency of seizures of patients with epilepsy.Methods. We prospectively assessed the seizure frequency of 100 consecutive patients with partial (n = 95) and primary (n = 5) generalized epilepsy during a trial with SRT for the treatment of a depressive (n = 97) or obsessive-compulsive (n = 3) disorder. We compared the monthly seizure frequency recorded while on SRT with those logged during the 3 and 12 months preceding the start of SRT. A definite causality between seizure worsening and SRT was considered in the following circumstances: (1) occurrence of de novo generalized tonic-clonic seizure (GTC); (2) recurrence of a GTC following a period of at least 1 year without this seizure type; and (3) an increase in the monthly seizure frequency beyond the maximal recorded monthly frequency during both 3- and 12-month periods preceding SRT. A probable causality between SRT and seizure worsening was considered in the case of an increase in monthly seizures beyond the maximal frequency recorded during the 3-month, but not the 12-month, period preceding SRT.Results. Six patients (6%) experienced an increase in seizure frequency after starting SRT. One and five patients met criteria for definite and probable causality between SRT and seizure worsening, respectively. Adjustment of antiepileptic drug doses resulted in a return to baseline seizure frequency in the latter five patients; four patients were kept on SRT at the same doses. The SRT dose of these six patients was significantly lower (57.1 +/- 23.8 mg/day vs 111.8 +/- 56.8 mg/day; F = 6.35, P = 0.01) than that of the other 94 patients.Conclusion. SRT can be safely used in the vast majority of patients with epilepsy." @default.
- W2046252007 created "2016-06-24" @default.
- W2046252007 creator A5017041163 @default.
- W2046252007 creator A5052869030 @default.
- W2046252007 creator A5079094960 @default.
- W2046252007 date "2000-04-01" @default.
- W2046252007 modified "2023-10-18" @default.
- W2046252007 title "The Use of Sertraline in Patients with Epilepsy: Is It Safe?" @default.
- W2046252007 cites W2011366794 @default.
- W2046252007 cites W2023226417 @default.
- W2046252007 cites W2044452957 @default.
- W2046252007 cites W2080202639 @default.
- W2046252007 cites W4300282546 @default.
- W2046252007 cites W47265956 @default.
- W2046252007 doi "https://doi.org/10.1006/ebeh.2000.0050" @default.
- W2046252007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12609138" @default.
- W2046252007 hasPublicationYear "2000" @default.
- W2046252007 type Work @default.
- W2046252007 sameAs 2046252007 @default.
- W2046252007 citedByCount "239" @default.
- W2046252007 countsByYear W20462520072012 @default.
- W2046252007 countsByYear W20462520072013 @default.
- W2046252007 countsByYear W20462520072014 @default.
- W2046252007 countsByYear W20462520072015 @default.
- W2046252007 countsByYear W20462520072016 @default.
- W2046252007 countsByYear W20462520072017 @default.
- W2046252007 countsByYear W20462520072018 @default.
- W2046252007 countsByYear W20462520072019 @default.
- W2046252007 countsByYear W20462520072020 @default.
- W2046252007 countsByYear W20462520072021 @default.
- W2046252007 countsByYear W20462520072022 @default.
- W2046252007 countsByYear W20462520072023 @default.
- W2046252007 crossrefType "journal-article" @default.
- W2046252007 hasAuthorship W2046252007A5017041163 @default.
- W2046252007 hasAuthorship W2046252007A5052869030 @default.
- W2046252007 hasAuthorship W2046252007A5079094960 @default.
- W2046252007 hasConcept C118552586 @default.
- W2046252007 hasConcept C15744967 @default.
- W2046252007 hasConcept C187212893 @default.
- W2046252007 hasConcept C2777669559 @default.
- W2046252007 hasConcept C2778186239 @default.
- W2046252007 hasConcept C2779177272 @default.
- W2046252007 hasConcept C42219234 @default.
- W2046252007 hasConcept C558461103 @default.
- W2046252007 hasConcept C71924100 @default.
- W2046252007 hasConceptScore W2046252007C118552586 @default.
- W2046252007 hasConceptScore W2046252007C15744967 @default.
- W2046252007 hasConceptScore W2046252007C187212893 @default.
- W2046252007 hasConceptScore W2046252007C2777669559 @default.
- W2046252007 hasConceptScore W2046252007C2778186239 @default.
- W2046252007 hasConceptScore W2046252007C2779177272 @default.
- W2046252007 hasConceptScore W2046252007C42219234 @default.
- W2046252007 hasConceptScore W2046252007C558461103 @default.
- W2046252007 hasConceptScore W2046252007C71924100 @default.
- W2046252007 hasIssue "2" @default.
- W2046252007 hasLocation W20462520071 @default.
- W2046252007 hasLocation W20462520072 @default.
- W2046252007 hasOpenAccess W2046252007 @default.
- W2046252007 hasPrimaryLocation W20462520071 @default.
- W2046252007 hasRelatedWork W2054922760 @default.
- W2046252007 hasRelatedWork W2119470083 @default.
- W2046252007 hasRelatedWork W2365776827 @default.
- W2046252007 hasRelatedWork W2412136802 @default.
- W2046252007 hasRelatedWork W2748952813 @default.
- W2046252007 hasRelatedWork W2899084033 @default.
- W2046252007 hasRelatedWork W3124002180 @default.
- W2046252007 hasRelatedWork W3137407127 @default.
- W2046252007 hasRelatedWork W4225006941 @default.
- W2046252007 hasRelatedWork W2294699528 @default.
- W2046252007 hasVolume "1" @default.
- W2046252007 isParatext "false" @default.
- W2046252007 isRetracted "false" @default.
- W2046252007 magId "2046252007" @default.
- W2046252007 workType "article" @default.